FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab-containing regimens. Mottok A,* Jurinovic V,* et al. Blood, 2017. *Equal Contribution.
In this paper, we describe that high expression of the FOXP1 transcription factor predicts adverse failure-free survival in follicular lymphoma patients treated with immunochemotherapy. We also show that FOXP1 high and low expressors differ in specific gene mutations and gene expression changes.